NCT07205315View on ClinicalTrials.gov

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

August 31, 2028

Conditions
Hematological Malignancy (Leukemia- Lymphoma)
Interventions
BIOLOGICAL

GT801 Injection

GT801 Injection

Trial Locations (1)

450018

RECRUITING

Zhengzhou Yihe Hospital, Zhengzhou

Sponsors

Lead Sponsor

Grit Biotechnology
All Listed Sponsors
collaborator

Zhengzhou Yihe Hospital

UNKNOWN

lead

Grit Biotechnology

INDUSTRY

NCT07205315 - A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies | Biotech Hunter | Biotech Hunter